|
Pharmaceuticals |
Pharmaceuticals continue to be the largest and most profitable business for Lotus. Particularly, strong growth will be posted by the cardiovascular franchises, thanks to the class-leading product, VALSARTAN (used to control hypertension).
Altogether there are four organs attached to this Corporation handling respectively the scientific research on new medicine, the production, wholesale and retail of medicine to treat chronic myeloid leukemia. Overall, the division once again successfully increased its market share last year. With a total of 12 projects in clinical development, we have a full, innovative and promising pipeline. The Company will continue to underwrite research and development, as we need to keep a sharp eye on the market’s evolution. |
|
|
| To keep abreast of China's pharmaceutical industry, we recommend subscribing to Pharma China, an English language weekly newsletter with the most up-to-date information. |
| This website contains forward-looking statements that involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the company's limited operating history, the limited financial resources, domestic or global economic conditions -- especially those relating to China, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws, restrictions and regulations on doing business in a foreign country, in particular China, and conditions of equity markets. More information about the potential factors that could affect the company's business and financial results is included in the Company's filings, available via the United States Securities & Exchange Commission. Occasionally, the Company may select and post articles or opinions of third parties, with no known connection with the Company. These are considered expert or qualified writers about the Chinese economy and its various opportunities and pitfalls. The Company neither endorses nor rejects these views or content, and the articles are offered only for the readers' edification and personal analyses. |
|
|
|
|
|
